Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00749346 | NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer | PHASE1 | COMPLETED | 42 | — | — | May 1, 2008 | Jul 1, 2011 | Sep 27, 2011 | 4 | Switzerland |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Treatment with concomitant Alimta and NovoTTF-100L |
| Name | Type | Description |
|---|---|---|
| NovoTTF-100L | DEVICE | TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing |
Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Stage IV or IIIB with malignant pleural effusion, also locally advanced NSCLC not otherwise amenable to local treatment (surgery or radiotherapy) * One line of prior chemotherapy * Measurable diseas...